Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A nationwide 104 weeks real‐world study of dupilumab in adults with atopic dermatitis: Ineffectiveness in head‐and‐neck dermatitis
Ida Vittrup, Niels Steen Krogh, Henrik Hedegaard Pliess Larsen, et al.
Journal of the European Academy of Dermatology and Venereology (2023) Vol. 37, Iss. 5, pp. 1046-1055
Open Access | Times Cited: 39

Showing 1-25 of 39 citing articles:

Management of Patients Affected by Moderate-to-Severe Atopic Dermatitis with JAK Inhibitors in Real-World Clinical Practice: An Italian Delphi Consensus
Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, et al.
Dermatology and Therapy (2024) Vol. 14, Iss. 4, pp. 919-932
Open Access | Times Cited: 19
Dupilumab-associated head and neck dermatitis shows a pronounced type 22 immune signature mediated by oligoclonally expanded T cells
Christine Bangert, Natalia Alkon, Sumanth Chennareddy, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 15
Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: Up to 5-year results from the daily practice BioDay registry
Junfen Zhang, Celeste M. Boesjes, Laura Loman, et al.
Journal of the American Academy of Dermatology (2024) Vol. 91, Iss. 2, pp. 300-311
Open Access | Times Cited: 11
Real-World Evidence of Tralokinumab Effectiveness and Safety: A Systematic Review and Meta-analysis
Amalie Thorsti Møller Rønnstad, Christopher G. Bunick, Raj Chovatiya, et al.
American Journal of Clinical Dermatology (2025)
Closed Access | Times Cited: 1
Ruxolitinib cream monotherapy for facial and/or neck atopic dermatitis: results from a decentralized, randomized phase 2 clinical trial
Zelma C. Chiesa Fuxench, Zhihong Lai, Yutzu Kuo, et al.
Journal of Dermatological Treatment (2025) Vol. 36, Iss. 1
Open Access | Times Cited: 1
Effectiveness and Safety of Upadacitinib in Combination with Topical Corticosteroids in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis
Teppei Hagino, Risa Hamada, Mai Yoshida, et al.
Clinical Cosmetic and Investigational Dermatology (2023) Vol. Volume 16, pp. 3201-3212
Open Access | Times Cited: 17
Therapeutic effectiveness of upadacitinib on individual types of rash in Japanese patients with moderate‐to‐severe atopic dermatitis
Teppei Hagino, Mai Yoshida, Risa Hamada, et al.
The Journal of Dermatology (2023) Vol. 50, Iss. 12, pp. 1576-1584
Open Access | Times Cited: 15
Effectiveness of switching from baricitinib 4 mg to upadacitinib 30 mg in patients with moderate-to-severe atopic dermatitis: a real-world clinical practice in Japan
Teppei Hagino, Mai Yoshida, Risa Hamada, et al.
Journal of Dermatological Treatment (2023) Vol. 34, Iss. 1
Open Access | Times Cited: 14
Effectiveness of Dose Increase in Upadacitinib from 15 mg to 30 mg for Patients with Moderate-to-Severe Atopic Dermatitis: A Real-World Clinical Practice in Japan
Teppei Hagino, Risa Hamada, Mai Yoshida, et al.
Clinical Drug Investigation (2024) Vol. 44, Iss. 4, pp. 261-269
Closed Access | Times Cited: 5
Long-Term Effectiveness and Reasons for Discontinuation of Dupilumab in Patients With Atopic Dermatitis
Celeste M. Boesjes, Esmé Kamphuis, Marlies de Graaf, et al.
JAMA Dermatology (2024) Vol. 160, Iss. 10, pp. 1044-1044
Closed Access | Times Cited: 5
Head and neck atopic dermatitis: still a challenging manifestation in the biologic era
Niccolò Gori, Elena Ippoliti, Ketty Peris, et al.
Expert Opinion on Biological Therapy (2023) Vol. 23, Iss. 7, pp. 575-577
Open Access | Times Cited: 12
Emerging Systemic Treatment Options in Atopic Dermatitis
Andaç Salman, Ana M. Giménez‐Arnau
Balkan Medical Journal (2024), pp. 239-247
Open Access | Times Cited: 4
Effectiveness of Switching From Upadacitinib to Tralokinumab in Patients With Moderate-to-Severe Atopic Dermatitis: A Real-World Clinical Practice
Teppei Hagino, Hidehisa Saeki, Eita Fujimoto, et al.
Annals of Dermatology (2025) Vol. 37
Open Access
Burden of mild and moderate atopic dermatitis in adults: results from a real-world study in the United States
Jonathan I. Silverberg, Peter J. Anderson, Joseph C. Cappelleri, et al.
Archives of Dermatological Research (2025) Vol. 317, Iss. 1
Open Access
Effectiveness and Safety of Tralokinumab in Atopic Dermatitis: 1-year Results From a Real-world Multicentre Study
Laura Marina Calabrese, Élisa Cinotti, Martina D’Onghia, et al.
Acta Dermato Venereologica (2025) Vol. 105, pp. adv42275-adv42275
Open Access
Early Achievement of High Treatment Targets in Moderate-to-Severe Atopic Dermatitis with Upadacitinib: Real-World Evidence from the Observational UP-TAINED Study
Stephan Weidinger, Tobias Schadeck, Felix Jacobs, et al.
Dermatology and Therapy (2025)
Open Access
Long-Term Disease Control and Minimal Disease Activity of Head and Neck Atopic Dermatitis in Patients Treated with Tralokinumab up to 4 Years
Raj Chovatiya, Simone Ribero, Andreas Wollenberg, et al.
American Journal of Clinical Dermatology (2025)
Open Access
Enabling precision medicine with biomarkers of response to treatment in atopic dermatitis: where are we now? A narrative review
Andrea Chiricozzi, Anna Levi, Chiara Palladino, et al.
Frontiers in Medicine (2025) Vol. 12
Open Access
Long-Term Effectiveness of Dupilumab in Patients with Atopic Dermatitis: Results up to 3 Years from the RELIEVE-AD Study
Alexa B. Kimball, Dimittri Delevry, Min Yang, et al.
Dermatology and Therapy (2023) Vol. 13, Iss. 9, pp. 2107-2120
Open Access | Times Cited: 10
Blocking the IL-4/IL-13 Axis versus the JAK/STAT Pathway in Atopic Dermatitis: How Can We Choose?
Laura Marina Calabrese, Martina D’Onghia, Laura Lazzeri, et al.
Journal of Personalized Medicine (2024) Vol. 14, Iss. 7, pp. 775-775
Open Access | Times Cited: 3
A prospective observational cohort study comparing the treatment effectiveness and safety of ciclosporin, dupilumab and methotrexate in adult and paediatric patients with atopic dermatitis: results from the UK–Irish A-STAR register
Helen Alexander, Rayka Malek, David Prieto‐Merino, et al.
British Journal of Dermatology (2024) Vol. 191, Iss. 6, pp. 988-999
Open Access | Times Cited: 3
Real-World Efficacy and Safety of Dupilumab Use in Japanese Adult Patients with Atopic Dermatitis: A Single-Center, Retrospective, 104-Week, Observational Study
Tetsuharu Ikegami, Ken Igawa
Diseases (2025) Vol. 13, Iss. 2, pp. 44-44
Open Access
Head and neck dermatitis: a variant of atopic dermatitis
Leszek Blicharz, Agnieszka Michalczyk, Małgorzata Maj, et al.
Italian Journal of Dermatology and Venereology (2025) Vol. 160, Iss. 2
Closed Access
Ruxolitinib cream monotherapy demonstrates rapid improvement in the extent and signs of mild to moderate atopic dermatitis across head and neck and other anatomic regions in adolescents and adults: pooled results from 2 phase 3 studies
Eric L. Simpson, Robert Bissonnette, Zelma C. Chiesa Fuxench, et al.
Journal of Dermatological Treatment (2024) Vol. 35, Iss. 1
Open Access | Times Cited: 3
Short‐term real‐world experience with baricitinib treatment in Danish adults with moderate–severe atopic dermatitis
Ida Vittrup, Jesper Elberling, Lone Skov, et al.
Journal of the European Academy of Dermatology and Venereology (2022) Vol. 37, Iss. 4
Open Access | Times Cited: 13
Page 1 - Next Page

Scroll to top